4D Molecular Therapeutics, Inc. (FDMT)
| Market Cap | 238.70M |
| Revenue (ttm) | 17.26M |
| Net Income (ttm) | -81.25M |
| Shares Out | 32.30M |
| EPS (ttm) | -2.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,673 |
| Open | 7.03 |
| Previous Close | 7.10 |
| Day's Range | 6.94 - 7.40 |
| 52-Week Range | 5.32 - 36.14 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 23.66 (+220.2%) |
| Earnings Date | Aug 11, 2022 |
About FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which i... [Read more...]
Financial Performance
In 2021, FDMT's revenue was $18.04 million, an increase of 32.52% compared to the previous year's $13.61 million. Losses were -$71.32 million, 25.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is 23.66, which is an increase of 220.16% from the latest price.
News
4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences
EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted gen...
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12.33% and 39.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for th...
4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted gene...
Analysts Estimate 4D Molecular Therapeutics, Inc. (FDMT) to Report a Decline in Earnings: What to Look Out for
4D Molecular Therapeutics, Inc. (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference
EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ge...
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-bas...
EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targ...
4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights
EMERYVILLE, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ge...
4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company's Board of Directors
EMERYVILLE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...
4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ...
4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with...
EMERYVILLE, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene t...
4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presenta...
EMERYVILLE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...
4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retini...
EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intra...
EMERYVILLE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...
4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights
EMERYVILLE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...
4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene t...
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...
4D Molecular's Fabry Disease Candidate Shows Early Proof-Of-Concept
4D Molecular Therapeutics Inc (NASDAQ: FDMT) has announced interim data from the Phase 1/2 trial of intravenous 4D-310 in Fabry disease patients. The Company said that 4D-310 demonstrated a manageable s...
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Dis...
- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution
4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with ...
EMERYVILLE, Calif., Oct. 10, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...
4D Molecular To Test Its Wet AMD Gene Therapy In Patients
The FDA has signed off 4D Molecular Therapeutics' (NASDAQ: FDMT) Investigational New Drug Application (IND) for 4D-150 for wet age-related macular degeneration (wet AMD). The active IND enables the ini...
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene T...
Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delive...
Initiation of 4D-710 Phase 1/2 clinical trial sites expected before year-end Initiation of 4D-710 Phase 1/2 clinical trial sites expected before year-end
4D Molecular Therapeutics to Participate in Chardan's 5th Annual Genetic Medicines Conference
EMERYVILLE, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...